Sofinnova Partners

Sofinnova Partners is a prominent European venture capital firm specializing in life sciences investments, focusing on healthcare and sustainability. Established in 1972 and headquartered in Paris, with additional offices in London and Milan, the firm has over €4 billion under management and has backed more than 500 companies over its 50-year history. Sofinnova Partners is known for its hands-on approach, actively partnering with entrepreneurs as lead or cornerstone investors to develop transformative innovations that positively impact the future.

The firm's investment strategies encompass the entire life sciences value chain, from seed to later-stage investments. Their funds include Sofinnova Capital, focusing on early-stage biopharma and medtech startups; Sofinnova MD Start, an in-house medtech accelerator; Sofinnova Crossover, supporting later-stage biotech and medtech companies; Sofinnova Industrial Biotech, targeting sustainability in chemicals, agriculture, food, and materials sectors; Sofinnova Telethon, bringing Italian science to the global stage; Sofinnova Digital Medicine, investing in startups at the intersection of biology, data, and computation; and Sofinnova Biovelocita, dedicated to creating and accelerating European biotech startups in partnership with leading research organizations.

Sofinnova Partners has a strong track record of creating market leaders, with notable investments including Genentech, Actelion, Vistaprint, CoreValve, Novexel, Fovea, Movetis, and Preglem. The firm's experienced team and hands-on approach in building portfolio companies through to exit have been instrumental in these successes. In May 2022, Sofinnova Partners formed a strategic partnership with Apollo Global Management, with Apollo acquiring a minority stake and committing up to €1 billion of capital to its investment funds, further solidifying Sofinnova's position as a leading global player in life sciences venture capital.

In October 2023, Sofinnova Partners raised €190 million for its Digital Medicine I fund, focusing on companies at the forefront of biology, data, and computation. This fund has already made five investments, demonstrating Sofinnova's commitment to supporting innovative solutions in the digital health space. The firm's diverse portfolio and strategic partnerships underscore its dedication to advancing healthcare and sustainability through strategic investments in life sciences.

Sofinnova Partners continues to be a driving force in European venture capital, leveraging its extensive experience and global network to support entrepreneurs and companies that are shaping the future of healthcare and sustainability.